Some 70% of ovarian cancer patients present with advanced disease. Chemotherapy can induce remissions in 30-60% of these patients (Young et al., 1974) but the majority will relapse and die from their disease. Although combination chemotherapy incorporating cis-platin can achieve somewhat higher response rates than single agents there is little evidence from randomised studies that this is translated into a major improvement in survival (Bolis et al., 1987; Sturgeon et al., 1982; Vogl et al., 1983) . There is therefore a need for new active agents in this condition.
Methylene dimethane sulphonate (MDMS) is the first member (Cn= 1) of a homologous series of dimethane sulphonic acid esters of general formula CH3SO20.(CH2)n.020S3HC (Figure 1) . Busulphan, the fourth member of the series is widely used in the management of chronic myeloid leukaemia. MDMS is of interest because its small molecular size allows access to alkylating sites not available to other agents. In particular it is able to interact with the hydrogen bonds linking DNA strands thus producing interstrand crosslinks (Bedford & Fox, 1982) . In pre-clinical testing MDMS was active in the rat Yoshida and Walker sarcoma systems (Fox, 1969 (Fox, ,1979 . In the phase I trial of MDMS the dose limiting toxicity was thrombocytopenia (Smith et al., 1987) Twenty patients were entered into the study but one was ineligible due to incorrect histology (mixed mullerian Br. J. Cancer (1988), 57, 512-513 C The Macmillan Press Ltd., 1988 No objective responses were seen during the study. Progressive disease occurred in 13 patients. Two patients had stable disease after two courses and one after three courses but were then withdrawn due to either a platelet nadir below 20 x 1091-1 with the previous course (1) or persistent thrombocytopenia (2). The remaining 3 patients were withdrawn after one course, two due to thrombocytopenia and one to the development of a second primary in the breast, and were not considered eligible for response. In view of the lack of objective remissions in sixteen evaluable patients the trial was closed.
Discussion
This phase II trial confirmed that the dose limiting toxicity of MDMS is thrombocytopenia. Moreover the platelet nadir occurs at least 21 days following therapy and although recovery was usual by week 6 in some cases platelets remained below 100 x 109 1 1 for several months. In addition platelet toxicity appeared to be cumulative with lower more prolonged nadirs with successive courses. Significant anaemia Table I .
Ten patients received one course of MDMS, 6 patients two courses, 2 patients three courses and 1 patient four courses. The reasons for discontinuing treatment were progressive disease 13 patients, early death I patient and persistent thrombocytopenia 5 patients. Six out of 9 patients who received two or more courses required dose reductions and 6 patients were given blood transfusions as a result of treatment related anaemia. Two patients required platelet transfusions, both following the second cycle of MDMS, when the platelet count fell below 20 x 1091-1. Platelet and WBC nadirs according to course are shown in Table II . There was no hepatic or renal toxicity observed during the trial. No episodes of infection requiring i.v. antibiotics occurred.
Non-haematological toxicity included nausea and vomiting in 4 patients (grade 1: 3 patients, grade 3: 1 patient) and also occurred and 6 of the 9 patients who received at least two cycles of therapy required transfusions. Neutropenia on the other hand was not a problem and there was no instance during the study of a WBC nadir below 1.0 x 1091 -1 and no serious episodes of infection occurred.
MDMS was subjectively well tolerated the major side effect being alopecia which affected 7 patients 6 of whom had had at least two courses. In only 2 patients was a wig required. Nausea and vomiting was mild and occurred in only 4 patients lasting a maximum of 12h.
Although 3 patients had stable disease for periods in excess of 8 weeks no objective remissions were seen during the study. MDMS would therefore appear to be inactive in patients with ovarian cancer who have received prior chemotherapy and cannot be recommended for further study in this condition. Moreover the delayed platelet nadir and cumulative nature of this toxicity would make it difficult to incorporate MDMS in combination regimens.
